demonstrated suggested inconclusive safety concern ongoing study display ongoing demontrated benefit only
COVID-19 mild to moderateCOVID-19 severe or critically
COVID 19 hospitalizedCOVID-19 mild to moderateCOVID-19 severe or critically
ivermectin Gonzalez ... Shahbaznejad Kirti I-TECH ... Chaccour Krolewiecki Galan Galan
ivermectin plus doxycycline Hashim A NCT04523831 ...

24 studies excluded by filtering options 0

6064 Glorial F, 2020 1100not a RCTrisk of bias not avaialble
6082 ICON, 2020 0130selection pending
6083 IFORS (Pott-Junior), 2020 213excludedhigh risk of bias
6095 Camprubi, 2020 1110not a RCTrisk of bias not avaialble
6096 Elgazzar - treatment, 2020 213excludedhigh risk of bias
6368 Niaee (vs placebo), 2020 213excludedhigh risk of bias
6369 Ahmed, 2020 113high risk of bias
6370 Chachar, 2020 113high risk of bias
6375 Cadegiani -Iver, 2020 2990excludednot a RCTrisk of bias not avaialble
6381 Espitia-Hernandez, 2020 1310not a RCTrisk of bias not avaialble
6382 Khan, 2020 0130selection pending
6382 Khan, 2020 0130selection pending
6383 Soto-Becerra, 2020 0122selection pending
6383 Soto-Becerra, 2020 0122selection pending
6384 Spoorthi, 2020 1310not a RCTrisk of bias not avaialble
6384 Spoorthi, 2020 1310not a RCTrisk of bias not avaialble
6449 Okumuş, 2020 113high risk of bias
6575 Bukhari, 2021 113high risk of bias
6624 Babalola, 2021 113high risk of bias
6625 Nasir, 2020 2310excludednot a RCTrisk of bias not avaialble
6626 RIVET-COV (Mohan) (12mg and 24mg), 2021 113high risk of bias
7313 Abd-Elsalam, 2021 113high risk of bias
7995 Hazan, 2021 2320excludednot a RCTrisk of bias not avaialble
9462 Mayer, 2022 000selection pending